Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01037—5-Aminolevulinate synthase (2.3.1.37)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development

Application Number	Priority Date	Filing Date	Title
US201361887288P	2013-10-04	2013-10-04
US201461983720P	2014-04-24	2014-04-24
PCT/US2014/059160WO2015051318A1 (en)	2013-10-04	2014-10-03	Compositions and methods for inhibiting expression of the alas1 gene

Publication Number	Publication Date
DK3052628T3true DK3052628T3 (en)	2020-06-02

Family

ID=51932569

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK14800179.5TDK3052628T3 (en)	2013-10-04	2014-10-03	COMPOSITIONS AND PROCEDURES FOR INHIBITING EXPRESSION OF ALAS1 GENET

Country Status (37)

Country	Link
US (4)	US10119143B2 (en)
EP (2)	EP3052628B1 (en)
JP (3)	JP6613227B2 (en)
KR (3)	KR102469850B1 (en)
CN (1)	CN105980559B (en)
AU (3)	AU2014331604B2 (en)
BR (2)	BR112016007226B1 (en)
CA (2)	CA2925357C (en)
CL (2)	CL2016000772A1 (en)
CR (1)	CR20160195A (en)
CY (2)	CY1122975T1 (en)
DK (1)	DK3052628T3 (en)
DO (2)	DOP2016000073A (en)
EA (1)	EA036477B1 (en)
ES (1)	ES2804510T3 (en)
GT (1)	GT201600066A (en)
HR (1)	HRP20200822T1 (en)
HU (2)	HUE049227T2 (en)
IL (4)	IL282747B2 (en)
LT (2)	LT3052628T (en)
MX (2)	MX390724B (en)
MY (2)	MY197646A (en)
NL (1)	NL301061I2 (en)
NO (1)	NO2020029I1 (en)
NZ (2)	NZ718995A (en)
PE (2)	PE20211249A1 (en)
PH (1)	PH12016500574A1 (en)
PL (1)	PL3052628T3 (en)
PT (1)	PT3052628T (en)
SG (2)	SG10201910929QA (en)
SI (1)	SI3052628T1 (en)
SM (1)	SMT202000271T1 (en)
TN (1)	TN2016000114A1 (en)
TW (3)	TWI768330B (en)
UA (1)	UA124961C2 (en)
WO (1)	WO2015051318A1 (en)
ZA (2)	ZA201602931B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
MX390724B (en)*	2013-10-04	2025-03-21	Alnylam Pharmaceuticals Inc	Compositions and methods for inhibiting expression of the alas1 gene
IL316808A (en)	2014-08-20	2025-01-01	Alnylam Pharmaceuticals Inc	Modified double-stranded rna agents and uses thereof
WO2016061487A1 (en)	2014-10-17	2016-04-21	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
WO2017048843A1 (en)	2015-09-14	2017-03-23	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the alas1 gene
JP7288852B2 (en)	2016-11-23	2023-06-08	アルニラム・ファーマシューティカルズ・インコーポレーテッド	Modified RNA agents with reduced off-target effects
WO2019136432A1 (en)	2018-01-08	2019-07-11	Novartis Ag	Immune-enhancing rnas for combination with chimeric antigen receptor therapy
JP2023515466A (en)*	2020-02-21	2023-04-13	アイオーニスファーマシューティカルズ，インコーポレーテッド	Method for reducing expression of HTT
EP4413378A1 (en)	2021-10-06	2024-08-14	Alnylam Pharmaceuticals, Inc.	Renal injury biomarkers as biomarkers for acute hepatic porphyria (ahp)
AU2024206732A1 (en)*	2023-01-06	2025-07-17	Icahn School Of Medicine At Mount Sinai	Methods for enhancing the efficacy of rnai therapy by targeting alas1/alas2
CN118460654B (en)*	2024-07-10	2025-02-14	凯莱英医药集团（天津）股份有限公司	A preparation method of Givosiran

Family Cites Families (245)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US513030A (en)		1894-01-16		Machine for waxing or coating paper
US564562A (en)		1896-07-21		Joseph p
US3687808A (en)	1969-08-14	1972-08-29	Univ Leland Stanford Junior	Synthetic polynucleotides
US4469863A (en)	1980-11-12	1984-09-04	Ts O Paul O P	Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4426330A (en)	1981-07-20	1984-01-17	Lipid Specialties, Inc.	Synthetic phospholipid compounds
US4534899A (en)	1981-07-20	1985-08-13	Lipid Specialties, Inc.	Synthetic phospholipid compounds
US5023243A (en)	1981-10-23	1991-06-11	Molecular Biosystems, Inc.	Oligonucleotide therapeutic agent and method of making same
US4476301A (en)	1982-04-29	1984-10-09	Centre National De La Recherche Scientifique	Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
JPS5927900A (en)	1982-08-09	1984-02-14	Wakunaga Seiyaku Kk	Oligonucleotide derivative and its preparation
FR2540122B1 (en)	1983-01-27	1985-11-29	Centre Nat Rech Scient	NOVEL COMPOUNDS COMPRISING A SEQUENCE OF OLIGONUCLEOTIDE LINKED TO AN INTERCALATION AGENT, THEIR SYNTHESIS PROCESS AND THEIR APPLICATION
US4605735A (en)	1983-02-14	1986-08-12	Wakunaga Seiyaku Kabushiki Kaisha	Oligonucleotide derivatives
US4948882A (en)	1983-02-22	1990-08-14	Syngene, Inc.	Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4824941A (en)	1983-03-10	1989-04-25	Julian Gordon	Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
US4587044A (en)	1983-09-01	1986-05-06	The Johns Hopkins University	Linkage of proteins to nucleic acids
US5118800A (en)	1983-12-20	1992-06-02	California Institute Of Technology	Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5118802A (en)	1983-12-20	1992-06-02	California Institute Of Technology	DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5550111A (en)	1984-07-11	1996-08-27	Temple University-Of The Commonwealth System Of Higher Education	Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (en)	1984-07-19	1989-02-17	Centre Nat Rech Scient	NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS
US5367066A (en)	1984-10-16	1994-11-22	Chiron Corporation	Oligonucleotides with selectably cleavable and/or abasic sites
US5258506A (en)	1984-10-16	1993-11-02	Chiron Corporation	Photolabile reagents for incorporation into oligonucleotide chains
US5430136A (en)	1984-10-16	1995-07-04	Chiron Corporation	Oligonucleotides having selectably cleavable and/or abasic sites
US4828979A (en)	1984-11-08	1989-05-09	Life Technologies, Inc.	Nucleotide analogs for nucleic acid labeling and detection
FR2575751B1 (en)	1985-01-08	1987-04-03	Pasteur Institut	NOVEL ADENOSINE DERIVATIVE NUCLEOSIDES, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
US5034506A (en)	1985-03-15	1991-07-23	Anti-Gene Development Group	Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en)	1985-03-15	1993-08-10	Anti-Gene Development Group	Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5166315A (en)	1989-12-20	1992-11-24	Anti-Gene Development Group	Sequence-specific binding polymers for duplex nucleic acids
US5405938A (en)	1989-12-20	1995-04-11	Anti-Gene Development Group	Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en)	1985-03-15	1993-02-09	Anti-Gene Deveopment Group	Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4762779A (en)	1985-06-13	1988-08-09	Amgen Inc.	Compositions and methods for functionalizing nucleic acids
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
US5317098A (en)	1986-03-17	1994-05-31	Hiroaki Shizuya	Non-radioisotope tagging of fragments
JPS638396A (en)	1986-06-30	1988-01-14	Wakunaga Pharmaceut Co Ltd	Poly-labeled oligonucleotide derivative
US4920016A (en)	1986-12-24	1990-04-24	Linear Technology, Inc.	Liposomes with enhanced circulation time
US4837028A (en)	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5264423A (en)	1987-03-25	1993-11-23	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en)	1987-03-25	1994-01-04	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US4904582A (en)	1987-06-11	1990-02-27	Synthetic Genetics	Novel amphiphilic nucleic acid conjugates
EP0366685B1 (en)	1987-06-24	1994-10-19	Howard Florey Institute Of Experimental Physiology And Medicine	Nucleoside derivatives
US5585481A (en)	1987-09-21	1996-12-17	Gen-Probe Incorporated	Linking reagents for nucleotide probes
US5188897A (en)	1987-10-22	1993-02-23	Temple University Of The Commonwealth System Of Higher Education	Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en)	1987-10-22	1990-05-15	Temple University-Of The Commonwealth System Of Higher Education	2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5525465A (en)	1987-10-28	1996-06-11	Howard Florey Institute Of Experimental Physiology And Medicine	Oligonucleotide-polyamide conjugates and methods of production and applications of the same
DE3738460A1 (en)	1987-11-12	1989-05-24	Max Planck Gesellschaft	MODIFIED OLIGONUCLEOTIDS
US5082830A (en)	1988-02-26	1992-01-21	Enzo Biochem, Inc.	End labeled nucleotide probe
JPH03503894A (en)	1988-03-25	1991-08-29	ユニバーシィティ　オブ　バージニア　アランミ　パテンツ　ファウンデイション	Oligonucleotide N-alkylphosphoramidate
US5278302A (en)	1988-05-26	1994-01-11	University Patents, Inc.	Polynucleotide phosphorodithioates
US5109124A (en)	1988-06-01	1992-04-28	Biogen, Inc.	Nucleic acid probe linked to a label having a terminal cysteine
US5216141A (en)	1988-06-06	1993-06-01	Benner Steven A	Oligonucleotide analogs containing sulfur linkages
US5175273A (en)	1988-07-01	1992-12-29	Genentech, Inc.	Nucleic acid intercalating agents
US5262536A (en)	1988-09-15	1993-11-16	E. I. Du Pont De Nemours And Company	Reagents for the preparation of 5'-tagged oligonucleotides
GB8824593D0 (en)	1988-10-20	1988-11-23	Royal Free Hosp School Med	Liposomes
US5512439A (en)	1988-11-21	1996-04-30	Dynal As	Oligonucleotide-linked magnetic particles and uses thereof
US5457183A (en)	1989-03-06	1995-10-10	Board Of Regents, The University Of Texas System	Hydroxylated texaphyrins
US5599923A (en)	1989-03-06	1997-02-04	Board Of Regents, University Of Tx	Texaphyrin metal complexes having improved functionalization
US5391723A (en)	1989-05-31	1995-02-21	Neorx Corporation	Oligonucleotide conjugates
US4958013A (en)	1989-06-06	1990-09-18	Northwestern University	Cholesteryl modified oligonucleotides
US5032401A (en)	1989-06-15	1991-07-16	Alpha Beta Technology	Glucan drug delivery system and adjuvant
US5451463A (en)	1989-08-28	1995-09-19	Clontech Laboratories, Inc.	Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
US5134066A (en)	1989-08-29	1992-07-28	Monsanto Company	Improved probes using nucleosides containing 3-dezauracil analogs
US5436146A (en)	1989-09-07	1995-07-25	The Trustees Of Princeton University	Helper-free stocks of recombinant adeno-associated virus vectors
US5254469A (en)	1989-09-12	1993-10-19	Eastman Kodak Company	Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
US5591722A (en)	1989-09-15	1997-01-07	Southern Research Institute	2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5356633A (en)	1989-10-20	1994-10-18	Liposome Technology, Inc.	Method of treatment of inflamed tissues
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5225212A (en)	1989-10-20	1993-07-06	Liposome Technology, Inc.	Microreservoir liposome composition and method
US5399676A (en)	1989-10-23	1995-03-21	Gilead Sciences	Oligonucleotides with inverted polarity
DK0497875T3 (en)	1989-10-24	2000-07-03	Gilead Sciences Inc	2'-modified oligonucleotides
US5264564A (en)	1989-10-24	1993-11-23	Gilead Sciences	Oligonucleotide analogs with novel linkages
US5292873A (en)	1989-11-29	1994-03-08	The Research Foundation Of State University Of New York	Nucleic acids labeled with naphthoquinone probe
US5177198A (en)	1989-11-30	1993-01-05	University Of N.C. At Chapel Hill	Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
CA2029273A1 (en)	1989-12-04	1991-06-05	Christine L. Brakel	Modified nucleotide compounds
US5486603A (en)	1990-01-08	1996-01-23	Gilead Sciences, Inc.	Oligonucleotide having enhanced binding affinity
US5587361A (en)	1991-10-15	1996-12-24	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US6783931B1 (en)	1990-01-11	2004-08-31	Isis Pharmaceuticals, Inc.	Amine-derivatized nucleosides and oligonucleosides
US5646265A (en)	1990-01-11	1997-07-08	Isis Pharmceuticals, Inc.	Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5587470A (en)	1990-01-11	1996-12-24	Isis Pharmaceuticals, Inc.	3-deazapurines
US7037646B1 (en)	1990-01-11	2006-05-02	Isis Pharmaceuticals, Inc.	Amine-derivatized nucleosides and oligonucleosides
US5852188A (en)	1990-01-11	1998-12-22	Isis Pharmaceuticals, Inc.	Oligonucleotides having chiral phosphorus linkages
US5459255A (en)	1990-01-11	1995-10-17	Isis Pharmaceuticals, Inc.	N-2 substituted purines
US5681941A (en)	1990-01-11	1997-10-28	Isis Pharmaceuticals, Inc.	Substituted purines and oligonucleotide cross-linking
US5578718A (en)	1990-01-11	1996-11-26	Isis Pharmaceuticals, Inc.	Thiol-derivatized nucleosides
US5670633A (en)	1990-01-11	1997-09-23	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides that detect and modulate gene expression
US5214136A (en)	1990-02-20	1993-05-25	Gilead Sciences, Inc.	Anthraquinone-derivatives oligonucleotides
WO1991013080A1 (en)	1990-02-20	1991-09-05	Gilead Sciences, Inc.	Pseudonucleosides and pseudonucleotides and their polymers
US5321131A (en)	1990-03-08	1994-06-14	Hybridon, Inc.	Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en)	1990-04-10	1995-11-28	The Dupont Merck Pharmaceutical Company	Oligonucleotide analogs with sulfamate linkages
US5665710A (en)	1990-04-30	1997-09-09	Georgetown University	Method of making liposomal oligodeoxynucleotide compositions
GB9009980D0 (en)	1990-05-03	1990-06-27	Amersham Int Plc	Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
DE69032425T2 (en)	1990-05-11	1998-11-26	Microprobe Corp., Bothell, Wash.	Immersion test strips for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides
US5981276A (en)	1990-06-20	1999-11-09	Dana-Farber Cancer Institute	Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5608046A (en)	1990-07-27	1997-03-04	Isis Pharmaceuticals, Inc.	Conjugated 4'-desmethyl nucleoside analog compounds
US5218105A (en)	1990-07-27	1993-06-08	Isis Pharmaceuticals	Polyamine conjugated oligonucleotides
EP0544824B1 (en)	1990-07-27	1997-06-11	Isis Pharmaceuticals, Inc.	Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5623070A (en)	1990-07-27	1997-04-22	Isis Pharmaceuticals, Inc.	Heteroatomic oligonucleoside linkages
US5602240A (en)	1990-07-27	1997-02-11	Ciba Geigy Ag.	Backbone modified oligonucleotide analogs
US5610289A (en)	1990-07-27	1997-03-11	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogues
US5688941A (en)	1990-07-27	1997-11-18	Isis Pharmaceuticals, Inc.	Methods of making conjugated 4' desmethyl nucleoside analog compounds
US5541307A (en)	1990-07-27	1996-07-30	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5138045A (en)	1990-07-27	1992-08-11	Isis Pharmaceuticals	Polyamine conjugated oligonucleotides
US5618704A (en)	1990-07-27	1997-04-08	Isis Pharmacueticals, Inc.	Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5677437A (en)	1990-07-27	1997-10-14	Isis Pharmaceuticals, Inc.	Heteroatomic oligonucleoside linkages
US5489677A (en)	1990-07-27	1996-02-06	Isis Pharmaceuticals, Inc.	Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
ATE131827T1 (en)	1990-08-03	1996-01-15	Sterling Winthrop Inc	COMPOUNDS AND METHODS FOR SUPPRESSING GENE EXPRESSION
US5245022A (en)	1990-08-03	1993-09-14	Sterling Drug, Inc.	Exonuclease resistant terminally substituted oligonucleotides
US5512667A (en)	1990-08-28	1996-04-30	Reed; Michael W.	Trifunctional intermediates for preparing 3'-tailed oligonucleotides
US5214134A (en)	1990-09-12	1993-05-25	Sterling Winthrop Inc.	Process of linking nucleosides with a siloxane bridge
US5561225A (en)	1990-09-19	1996-10-01	Southern Research Institute	Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
AU662298B2 (en)	1990-09-20	1995-08-31	Gilead Sciences, Inc.	Modified internucleoside linkages
US5432272A (en)	1990-10-09	1995-07-11	Benner; Steven A.	Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
CA2095212A1 (en)	1990-11-08	1992-05-09	Sudhir Agrawal	Incorporation of multiple reporter groups on synthetic oligonucleotides
GB9100304D0 (en)	1991-01-08	1991-02-20	Ici Plc	Compound
US7015315B1 (en)	1991-12-24	2006-03-21	Isis Pharmaceuticals, Inc.	Gapped oligonucleotides
JP3220180B2 (en)	1991-05-23	2001-10-22	三菱化学株式会社	Drug-containing protein-bound liposomes
US5714331A (en)	1991-05-24	1998-02-03	Buchardt, Deceased; Ole	Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en)	1993-11-22	1998-02-17	Buchardt, Deceased; Ole	Peptide nucleic acids having amino acid side chains
US5539082A (en)	1993-04-26	1996-07-23	Nielsen; Peter E.	Peptide nucleic acids
US5371241A (en)	1991-07-19	1994-12-06	Pharmacia P-L Biochemicals Inc.	Fluorescein labelled phosphoramidites
US5571799A (en)	1991-08-12	1996-11-05	Basco, Ltd.	(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
EP0538194B1 (en)	1991-10-17	1997-06-04	Novartis AG	Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein
US5594121A (en)	1991-11-07	1997-01-14	Gilead Sciences, Inc.	Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5252479A (en)	1991-11-08	1993-10-12	Research Corporation Technologies, Inc.	Safe vector for gene therapy
US5484908A (en)	1991-11-26	1996-01-16	Gilead Sciences, Inc.	Oligonucleotides containing 5-propynyl pyrimidines
US6235887B1 (en)	1991-11-26	2001-05-22	Isis Pharmaceuticals, Inc.	Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5359044A (en)	1991-12-13	1994-10-25	Isis Pharmaceuticals	Cyclobutyl oligonucleotide surrogates
US6277603B1 (en)	1991-12-24	2001-08-21	Isis Pharmaceuticals, Inc.	PNA-DNA-PNA chimeric macromolecules
AU669353B2 (en)	1991-12-24	1996-06-06	Isis Pharmaceuticals, Inc.	Gapped 2' modified oligonucleotides
US5565552A (en)	1992-01-21	1996-10-15	Pharmacyclics, Inc.	Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5595726A (en)	1992-01-21	1997-01-21	Pharmacyclics, Inc.	Chromophore probe for detection of nucleic acid
FR2687679B1 (en)	1992-02-05	1994-10-28	Centre Nat Rech Scient	OLIGOTHIONUCLEOTIDES.
DE4203923A1 (en)	1992-02-11	1993-08-12	Henkel Kgaa	METHOD FOR PRODUCING POLYCARBOXYLATES ON A POLYSACCHARIDE BASE
US5633360A (en)	1992-04-14	1997-05-27	Gilead Sciences, Inc.	Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en)	1992-06-01	1995-07-18	Gilead Sciences, Inc.	Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5587308A (en)	1992-06-02	1996-12-24	The United States Of America As Represented By The Department Of Health & Human Services	Modified adeno-associated virus vector capable of expression from a novel promoter
EP0577558A2 (en)	1992-07-01	1994-01-05	Ciba-Geigy Ag	Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
US5272250A (en)	1992-07-10	1993-12-21	Spielvogel Bernard F	Boronated phosphoramidate compounds
EP0654077A4 (en)	1992-07-17	1996-03-13	Ribozyme Pharm Inc	Method and reagent for treatment of animal diseases.
US6346614B1 (en)	1992-07-23	2002-02-12	Hybridon, Inc.	Hybrid oligonucleotide phosphorothioates
JPH08503855A (en)	1992-12-03	1996-04-30	ジェンザイム・コーポレイション	Gene therapy for cystic fibrosis
US5478745A (en)	1992-12-04	1995-12-26	University Of Pittsburgh	Recombinant viral vector system
US5574142A (en)	1992-12-15	1996-11-12	Microprobe Corporation	Peptide linkers for improved oligonucleotide delivery
JP3351476B2 (en)	1993-01-22	2002-11-25	三菱化学株式会社	Phospholipid derivatives and liposomes containing the same
US5476925A (en)	1993-02-01	1995-12-19	Northwestern University	Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
DE69422163T2 (en)	1993-02-19	2000-06-15	Nippon Shinyaku Co., Ltd.	GLYCEROL DERIVATIVE, DEVICE AND PHARMACEUTICAL COMPOSITION
US5395619A (en)	1993-03-03	1995-03-07	Liposome Technology, Inc.	Lipid-polymer conjugates and liposomes
GB9304618D0 (en)	1993-03-06	1993-04-21	Ciba Geigy Ag	Chemical compounds
DE69404289T2 (en)	1993-03-30	1998-02-19	Sanofi Sa	ACYCLIC NUCLEOSIDE ANALOGS AND THEIR OLIGONUCLEOTIDE SEQUENCES
WO1994022891A1 (en)	1993-03-31	1994-10-13	Sterling Winthrop Inc.	Oligonucleotides with amide linkages replacing phosphodiester linkages
DE4311944A1 (en)	1993-04-10	1994-10-13	Degussa	Coated sodium percarbonate particles, process for their preparation and detergent, cleaning and bleaching compositions containing them
US6191105B1 (en)	1993-05-10	2001-02-20	Protein Delivery, Inc.	Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5955591A (en)	1993-05-12	1999-09-21	Imbach; Jean-Louis	Phosphotriester oligonucleotides, amidites and method of preparation
US6015886A (en)	1993-05-24	2000-01-18	Chemgenes Corporation	Oligonucleotide phosphate esters
US6294664B1 (en)	1993-07-29	2001-09-25	Isis Pharmaceuticals, Inc.	Synthesis of oligonucleotides
US5502177A (en)	1993-09-17	1996-03-26	Gilead Sciences, Inc.	Pyrimidine derivatives for labeled binding partners
CA2176256A1 (en)	1993-11-16	1995-05-26	Lyle John Arnold, Jr.	Synthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages
CA2137297C (en)	1993-12-06	2000-04-18	Tsuyoshi Miyazaki	Reactive vesicle and functional substance-fixed vesicle
US5457187A (en)	1993-12-08	1995-10-10	Board Of Regents University Of Nebraska	Oligonucleotides containing 5-fluorouracil
US5446137B1 (en)	1993-12-09	1998-10-06	Behringwerke Ag	Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en)	1994-01-11	1996-05-21	Isis Pharmaceuticals, Inc.	Pyrrolidine-containing monomers and oligomers
US5596091A (en)	1994-03-18	1997-01-21	The Regents Of The University Of California	Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5599922A (en)	1994-03-18	1997-02-04	Lynx Therapeutics, Inc.	Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5627053A (en)	1994-03-29	1997-05-06	Ribozyme Pharmaceuticals, Inc.	2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en)	1994-03-31	1997-04-29	Amgen Inc.	Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US6054299A (en)	1994-04-29	2000-04-25	Conrad; Charles A.	Stem-loop cloning vector and method
US5525711A (en)	1994-05-18	1996-06-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pteridine nucleotide analogs as fluorescent DNA probes
US5543152A (en)	1994-06-20	1996-08-06	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
US5597696A (en)	1994-07-18	1997-01-28	Becton Dickinson And Company	Covalent cyanine dye oligonucleotide conjugates
US5580731A (en)	1994-08-25	1996-12-03	Chiron Corporation	N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5597909A (en)	1994-08-25	1997-01-28	Chiron Corporation	Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5820873A (en)	1994-09-30	1998-10-13	The University Of British Columbia	Polyethylene glycol modified ceramide lipids and liposome uses thereof
US6608035B1 (en)	1994-10-25	2003-08-19	Hybridon, Inc.	Method of down-regulating gene expression
US5665557A (en)	1994-11-14	1997-09-09	Systemix, Inc.	Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof
JP3269301B2 (en)	1994-12-28	2002-03-25	豊田合成株式会社	Rubber compound for glass run
US6166197A (en)	1995-03-06	2000-12-26	Isis Pharmaceuticals, Inc.	Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
JPH10512894A (en)	1995-03-06	1998-12-08	アイシス・ファーマシューティカルス・インコーポレーテッド	Improved method for the synthesis of 2'-O-substituted pyrimidines and their oligomeric compounds
US7422902B1 (en)	1995-06-07	2008-09-09	The University Of British Columbia	Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5756122A (en)	1995-06-07	1998-05-26	Georgetown University	Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
US5981501A (en)	1995-06-07	1999-11-09	Inex Pharmaceuticals Corp.	Methods for encapsulating plasmids in lipid bilayers
US5976567A (en)	1995-06-07	1999-11-02	Inex Pharmaceuticals Corp.	Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
AU705644B2 (en)	1995-08-01	1999-05-27	Novartis Ag	Liposomal oligonucleotide compositions
US5858397A (en)	1995-10-11	1999-01-12	University Of British Columbia	Liposomal formulations of mitoxantrone
CA2234931C (en)	1995-10-16	2010-01-19	Dana-Farber Cancer Institute	Novel expression vectors and methods of use
US6160109A (en)	1995-10-20	2000-12-12	Isis Pharmaceuticals, Inc.	Preparation of phosphorothioate and boranophosphate oligomers
US5858401A (en)	1996-01-22	1999-01-12	Sidmak Laboratories, Inc.	Pharmaceutical composition for cyclosporines
US5994316A (en)	1996-02-21	1999-11-30	The Immune Response Corporation	Method of preparing polynucleotide-carrier complexes for delivery to cells
US6444423B1 (en)	1996-06-07	2002-09-03	Molecular Dynamics, Inc.	Nucleosides comprising polydentate ligands
US6639062B2 (en)	1997-02-14	2003-10-28	Isis Pharmaceuticals, Inc.	Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6172209B1 (en)	1997-02-14	2001-01-09	Isis Pharmaceuticals Inc.	Aminooxy-modified oligonucleotides and methods for making same
US6576752B1 (en)	1997-02-14	2003-06-10	Isis Pharmaceuticals, Inc.	Aminooxy functionalized oligomers
JP3756313B2 (en)	1997-03-07	2006-03-15	武今西	Novel bicyclonucleosides and oligonucleotide analogues
WO1999001579A1 (en)	1997-07-01	1999-01-14	Isis Pharmaceuticals, Inc.	Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6794499B2 (en)	1997-09-12	2004-09-21	Exiqon A/S	Oligonucleotide analogues
ATE293123T1 (en)	1997-09-12	2005-04-15	Exiqon As	BI- AND TRI-CYCLIC - NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGS
US6528640B1 (en)	1997-11-05	2003-03-04	Ribozyme Pharmaceuticals, Incorporated	Synthetic ribonucleic acids with RNAse activity
US6617438B1 (en)	1997-11-05	2003-09-09	Sirna Therapeutics, Inc.	Oligoribonucleotides with enzymatic activity
US6320017B1 (en)	1997-12-23	2001-11-20	Inex Pharmaceuticals Corp.	Polyamide oligomers
US7273933B1 (en)	1998-02-26	2007-09-25	Isis Pharmaceuticals, Inc.	Methods for synthesis of oligonucleotides
US7045610B2 (en)	1998-04-03	2006-05-16	Epoch Biosciences, Inc.	Modified oligonucleotides for mismatch discrimination
US6531590B1 (en)	1998-04-24	2003-03-11	Isis Pharmaceuticals, Inc.	Processes for the synthesis of oligonucleotide compounds
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
WO2000003683A2 (en)	1998-07-20	2000-01-27	Inex Pharmaceuticals Corporation	Liposomal encapsulated nucleic acid-complexes
US6537777B1 (en)	1998-07-27	2003-03-25	Hemebiotech A/S	Human porphobilinogen deaminase sequences
MXPA01003643A (en)	1998-10-09	2003-07-21	Ingene Inc	PRODUCTION OF ssDNA IN VIVO.
AU6430599A (en)	1998-10-09	2000-05-01	Cytogenix, Inc.	Enzymatic synthesis of ssdna
US6465628B1 (en)	1999-02-04	2002-10-15	Isis Pharmaceuticals, Inc.	Process for the synthesis of oligomeric compounds
EP1156812A4 (en)	1999-02-23	2004-09-29	Isis Pharmaceuticals Inc	Multiparticulate formulation
US7084125B2 (en)	1999-03-18	2006-08-01	Exiqon A/S	Xylo-LNA analogues
US7053207B2 (en)	1999-05-04	2006-05-30	Exiqon A/S	L-ribo-LNA analogues
US6593466B1 (en)	1999-07-07	2003-07-15	Isis Pharmaceuticals, Inc.	Guanidinium functionalized nucleotides and precursors thereof
US6147200A (en)	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
AU2001227965A1 (en)	2000-01-21	2001-07-31	Geron Corporation	2'-arabino-fluorooligonucleotide n3'-p5'phosphoramidates: their synthesis and use
IT1318539B1 (en)	2000-05-26	2003-08-27	Italfarmaco Spa	PROLONGED RELEASE PHARMACEUTICAL COMPOSITIONS FOR THE PARENTERAL ADMINISTRATION OF BIOLOGICALLY HYDROPHILE SUBSTANCES
AU2001293687A1 (en)	2000-10-04	2002-04-15	Cureon A/S	Improved synthesis of purine locked nucleic acid analogues
WO2003015698A2 (en)	2001-08-13	2003-02-27	University Of Pittsburgh	Application of lipid vehicles and use for drug delivery
WO2004007718A2 (en)	2002-07-10	2004-01-22	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Rna-interference by single-stranded rna molecules
US6878805B2 (en)	2002-08-16	2005-04-12	Isis Pharmaceuticals, Inc.	Peptide-conjugated oligomeric compounds
EP2305812A3 (en)*	2002-11-14	2012-06-06	Dharmacon, Inc.	Fuctional and hyperfunctional sirna
WO2005001110A2 (en)	2003-05-29	2005-01-06	The Salk Institute For Biological Studies	Transcriptional regulation of gene expression by small double-stranded modulatory rna
BRPI0412282A (en)	2003-07-02	2006-09-19	Musc Found For Res Dev	specific and nonspecifically induced dsrna immunity in crustaceans and other invertebrates, and bioliberation vehicles for use in these
EP2567693B1 (en)	2003-07-16	2015-10-21	Protiva Biotherapeutics Inc.	Lipid encapsulated interfering RNA
EP2530157B1 (en)	2003-07-31	2016-09-28	Regulus Therapeutics Inc.	Oligomeric compounds and compositions for use in modulation of miRNAs
ATE555118T1 (en)	2003-08-28	2012-05-15	Takeshi Imanishi	NEW SYNTHETIC NUCLEIC ACIDS OF THE CROSS-LINKED N-O BOND TYPE
KR20070085113A (en)	2004-05-11	2007-08-27	가부시키가이샤 알파젠	Polynucleotides causing RNA interference, and gene expression inhibition method using the same
US7740861B2 (en)	2004-06-16	2010-06-22	University Of Massachusetts	Drug delivery product and methods
DK1866414T3 (en)	2005-03-31	2012-04-23	Calando Pharmaceuticals Inc	Inhibitors of ribonucleotide reductase subunit 2 and uses thereof.
JP5336853B2 (en)	2005-11-02	2013-11-06	プロチババイオセラピューティクスインコーポレイティッド	Modified siRNA molecules and methods of use thereof
AU2006336624B2 (en)	2005-11-17	2010-11-25	Board Of Regents, The University Of Texas System	Modulation of gene expression by oligomers targeted to chromosomal DNA
ES2516815T3 (en)	2006-01-27	2014-10-31	Isis Pharmaceuticals, Inc.	Analogs of bicyclic nucleic acids modified at position 6
TWI322690B (en)	2006-05-11	2010-04-01	Flysun Dev Co Ltd	Short interference ribonucleic acids for treating allergic dieases
EP2520935A3 (en)	2006-08-09	2013-02-13	Homestead Clinical Corporation	Organ-specific proteins and methods of their use
CA2927045A1 (en)	2006-10-03	2008-04-10	Muthiah Manoharan	Lipid containing formulations
EP2121923A1 (en)	2007-03-02	2009-11-25	MDRNA, Inc.	Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
KR101750640B1 (en)	2007-05-22	2017-06-23	아크투루스 쎄라퓨틱스, 인크.	Oligomer for therapeutics
JP5519523B2 (en)	2007-12-04	2014-06-11	アルニラムファーマスーティカルズインコーポレイテッド	Carbohydrate conjugates as oligonucleotide delivery agents
JP5697988B2 (en)	2007-12-27	2015-04-08	プロチババイオセラピューティクスインコーポレイティッド	Method for silencing polo-like kinase expression using interfering RNA
CA2713379A1 (en)	2008-01-31	2009-11-05	Alnylam Pharmaceuticals, Inc.	Optimized methods for delivery of dsrna targeting the pcsk9 gene
US20110130440A1 (en)	2008-03-26	2011-06-02	Alnylam Pharmaceuticals, Inc.	Non-natural ribonucleotides, and methods of use thereof
NZ588583A (en)	2008-04-15	2012-08-31	Protiva Biotherapeutics Inc	Novel lipid formulations for nucleic acid delivery
WO2010148013A2 (en)*	2009-06-15	2010-12-23	Alnylam Pharmaceuticals, Inc.	Lipid formulated dsrna targeting the pcsk9 gene
WO2011005861A1 (en)	2009-07-07	2011-01-13	Alnylam Pharmaceuticals, Inc.	Oligonucleotide end caps
PT2539451E (en)	2010-02-24	2016-03-28	Arrowhead Res Corp	Compositions for targeted delivery of sirna
WO2012177906A1 (en)	2011-06-21	2012-12-27	Alnylam Pharmaceuticals, Inc.	Assays and methods for determining activity of a therapeutic agent in a subject
EP2780454A2 (en)	2011-11-18	2014-09-24	Alnylam Pharmaceuticals, Inc.	Modified rnai agents
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
MX390724B (en)	2013-10-04	2025-03-21	Alnylam Pharmaceuticals Inc	Compositions and methods for inhibiting expression of the alas1 gene
WO2017048843A1 (en)	2015-09-14	2017-03-23	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the alas1 gene

2014
- 2014-10-03MXMX2016004319Apatent/MX390724B/enunknown
- 2014-10-03MYMYPI2020006311Apatent/MY197646A/enunknown
- 2014-10-03HRHRP20200822TTpatent/HRP20200822T1/enunknown
- 2014-10-03CACA2925357Apatent/CA2925357C/enactiveActive
- 2014-10-03ILIL282747Apatent/IL282747B2/enunknown
- 2014-10-03PLPL14800179Tpatent/PL3052628T3/enunknown
- 2014-10-03NZNZ718995Apatent/NZ718995A/enunknown
- 2014-10-03WOPCT/US2014/059160patent/WO2015051318A1/enactiveApplication Filing
- 2014-10-03SGSG10201910929QApatent/SG10201910929QA/enunknown
- 2014-10-03KRKR1020217030663Apatent/KR102469850B1/enactiveActive
- 2014-10-03CACA3227061Apatent/CA3227061A1/enactivePending
- 2014-10-03AUAU2014331604Apatent/AU2014331604B2/enactiveActive
- 2014-10-03CNCN201480062979.3Apatent/CN105980559B/enactiveActive
- 2014-10-03SMSM20200271Tpatent/SMT202000271T1/enunknown
- 2014-10-03KRKR1020167011726Apatent/KR102307389B1/enactiveActive
- 2014-10-03BRBR112016007226-0Apatent/BR112016007226B1/enactiveIP Right Grant
- 2014-10-03SGSG11201602631XApatent/SG11201602631XA/enunknown
- 2014-10-03TNTN2016000114Apatent/TN2016000114A1/enunknown
- 2014-10-03BRBR122020001264-1Apatent/BR122020001264B1/enactiveIP Right Grant
- 2014-10-03PEPE2021000554Apatent/PE20211249A1/enunknown
- 2014-10-03EPEP14800179.5Apatent/EP3052628B1/enactiveActive
- 2014-10-03DKDK14800179.5Tpatent/DK3052628T3/enactive
- 2014-10-03LTLTEP14800179.5Tpatent/LT3052628T/enunknown
- 2014-10-03EAEA201690685Apatent/EA036477B1/enunknown
- 2014-10-03EPEP20154129.9Apatent/EP3693463A1/enactivePending
- 2014-10-03PTPT148001795Tpatent/PT3052628T/enunknown
- 2014-10-03TWTW109113729Apatent/TWI768330B/enactive
- 2014-10-03ESES14800179Tpatent/ES2804510T3/enactiveActive
- 2014-10-03MYMYPI2016000562Apatent/MY183490A/enunknown
- 2014-10-03TWTW103134649Apatent/TWI694080B/enactive
- 2014-10-03CRCR20160195Apatent/CR20160195A/enunknown
- 2014-10-03JPJP2016519974Apatent/JP6613227B2/enactiveActive
- 2014-10-03UAUAA201604801Apatent/UA124961C2/enunknown
- 2014-10-03USUS15/027,176patent/US10119143B2/enactiveActive
- 2014-10-03PEPE2016000454Apatent/PE20161130A1/enunknown
- 2014-10-03ILIL302726Apatent/IL302726B1/enunknown
- 2014-10-03NZNZ757749Apatent/NZ757749A/enunknown
- 2014-10-03TWTW111121394Apatent/TW202310853A/enunknown
- 2014-10-03HUHUE14800179Apatent/HUE049227T2/enunknown
- 2014-10-03KRKR1020227040207Apatent/KR20220159478A/enactivePending
- 2014-10-03SISI201431579Tpatent/SI3052628T1/enunknown
2016
- 2016-03-24ILIL244749Apatent/IL244749B/enactiveIP Right Grant
- 2016-03-29PHPH12016500574Apatent/PH12016500574A1/enunknown
- 2016-04-01CLCL2016000772Apatent/CL2016000772A1/enunknown
- 2016-04-04MXMX2022001017Apatent/MX2022001017A/enunknown
- 2016-04-04DODO2016000073Apatent/DOP2016000073A/enunknown
- 2016-04-04GTGT201600066Apatent/GT201600066A/enunknown
- 2016-04-29ZAZA2016/02931Apatent/ZA201602931B/enunknown
2018
- 2018-01-19CLCL2018000158Apatent/CL2018000158A1/enunknown
- 2018-05-04ZAZA2018/02919Apatent/ZA201802919B/enunknown
- 2018-09-20USUS16/137,046patent/US11028392B2/enactiveActive
2019
- 2019-11-01JPJP2019199538Apatent/JP7289254B2/enactiveActive
2020
- 2020-05-27CYCY20201100482Tpatent/CY1122975T1/enunknown
- 2020-08-18CYCY2020029Cpatent/CY2020029I1/enunknown
- 2020-08-26LTLTPA2020527Cpatent/LTC3052628I2/enunknown
- 2020-08-26NLNL301061Cpatent/NL301061I2/enunknown
- 2020-08-26NONO2020029Cpatent/NO2020029I1/enunknown
- 2020-08-26HUHUS2000034Cpatent/HUS2000034I1/enunknown
- 2020-12-11AUAU2020286311Apatent/AU2020286311C1/enactiveActive
2021
- 2021-05-04USUS17/307,846patent/US20230026968A1/ennot_activeAbandoned
2022
- 2022-04-19DODO2022000085Apatent/DOP2022000085A/enunknown
2023
- 2023-05-30JPJP2023088554Apatent/JP7739356B2/enactiveActive
- 2023-11-16AUAU2023266354Apatent/AU2023266354A1/enactivePending
2024
- 2024-04-09USUS18/630,504patent/US20250122505A1/enactivePending
2025
- 2025-06-12ILIL321463Apatent/IL321463A/enunknown

Publication number	Publication date
EP3693463A1 (en)	2020-08-12
JP7289254B2 (en)	2023-06-09
LTC3052628I2 (en)	2022-04-11
KR20220159478A (en)	2022-12-02
WO2015051318A1 (en)	2015-04-09
NZ757749A (en)	2022-07-01
EA201690685A1 (en)	2016-07-29
AU2014331604B2 (en)	2021-01-07
EP3052628A1 (en)	2016-08-10
TW201524991A (en)	2015-07-01
BR112016007226B1 (en)	2021-12-07
CA3227061A1 (en)	2015-04-09
CY2020029I2 (en)	2020-11-25
DOP2016000073A (en)	2016-10-30
PT3052628T (en)	2020-06-01
IL282747A (en)	2021-06-30
MX390724B (en)	2025-03-21
ZA201602931B (en)	2018-07-25
KR102307389B1 (en)	2021-09-30
IL302726B1 (en)	2025-08-01
MY197646A (en)	2023-06-30
AU2020286311B2 (en)	2023-08-31
MX2016004319A (en)	2016-07-12
SMT202000271T1 (en)	2020-07-08
TW202106697A (en)	2021-02-16
TN2016000114A1 (en)	2017-07-05
US20190144870A1 (en)	2019-05-16
CA2925357C (en)	2024-02-27
AU2020286311A1 (en)	2021-01-21
ZA201802919B (en)	2019-07-31
EP3052628B1 (en)	2020-02-26
IL302726A (en)	2023-07-01
UA124961C2 (en)	2021-12-22
NO2020029I1 (en)	2020-08-26
SG11201602631XA (en)	2016-05-30
US20250122505A1 (en)	2025-04-17
NL301061I2 (en)	2020-10-08
CN105980559A (en)	2016-09-28
IL282747B1 (en)	2023-06-01
CY2020029I1 (en)	2020-11-25
IL244749B (en)	2021-05-31
TWI768330B (en)	2022-06-21
TWI694080B (en)	2020-05-21
PH12016500574A1 (en)	2016-05-23
BR112016007226A2 (en)	2017-09-12
NL301061I1 (en)	2020-08-27
LTPA2020527I1 (en)	2020-09-25
BR122020001264B1 (en)	2022-11-22
IL321463A (en)	2025-08-01
KR20210122877A (en)	2021-10-12
MY183490A (en)	2021-02-22
MX2022001017A (en)	2022-02-22
JP2020096582A (en)	2020-06-25
PE20211249A1 (en)	2021-07-13
HRP20200822T1 (en)	2020-08-07
SI3052628T1 (en)	2020-07-31
HUS2000034I1 (en)	2020-09-28
US20160244766A1 (en)	2016-08-25
CA2925357A1 (en)	2015-04-09
EA036477B1 (en)	2020-11-16
JP7739356B2 (en)	2025-09-16
AU2023266354A1 (en)	2023-12-07
CY1122975T1 (en)	2020-11-25
CL2016000772A1 (en)	2016-12-02
CN105980559B (en)	2020-11-06
KR102469850B1 (en)	2022-11-23
ES2804510T3 (en)	2021-02-08
IL282747B2 (en)	2023-10-01
JP2023120219A (en)	2023-08-29
PL3052628T3 (en)	2020-08-24
JP2016539623A (en)	2016-12-22
TW202310853A (en)	2023-03-16
KR20160079793A (en)	2016-07-06
HUE049227T2 (en)	2020-09-28
PE20161130A1 (en)	2016-11-25
AU2014331604A1 (en)	2016-04-21
NZ718995A (en)	2022-07-01
CL2018000158A1 (en)	2018-07-20
DOP2022000085A (en)	2022-09-15
GT201600066A (en)	2018-12-18
LT3052628T (en)	2020-09-10
AU2020286311C1 (en)	2025-01-23
US11028392B2 (en)	2021-06-08
IL244749A0 (en)	2016-04-21
CR20160195A (en)	2016-09-05
SG10201910929QA (en)	2020-01-30
JP6613227B2 (en)	2019-11-27
US10119143B2 (en)	2018-11-06
US20230026968A1 (en)	2023-01-26
HK1221738A1 (en)	2017-06-09

Publication	Publication Date	Title
DK3356529T3 (en)	2021-11-08	COMPOSITIONS AND METHODS FOR INHIBITING LENA EXPRESSION OF LPA
DK3052628T3 (en)	2020-06-02	COMPOSITIONS AND PROCEDURES FOR INHIBITING EXPRESSION OF ALAS1 GENET
DK2958588T3 (en)	2017-11-20	Combination of vaccination and inhibition of PD-1 pathway
DK3556869T3 (en)	2023-10-02	COMPOSITIONS AND METHODS FOR SEQUENCE OF POLYNUCLEOTIDES
DK2961831T3 (en)	2020-09-07	Compositions and methods of immunotherapy
DK3102576T3 (en)	2019-07-22	DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA
DK3008168T3 (en)	2020-05-04	SC-CELLS AND COMPOSITIONS AND PROCEDURE FOR CREATING THEREOF
DK2929031T5 (en)	2021-08-23	PCSK9-IRNA COMPOSITIONS AND METHODS OF USING IT
DK2971167T3 (en)	2019-11-04	COMPOSITIONS AND PROCEDURES FOR TARGETING NUCLEIC ACID WITH NUCLEIC ACID
PL2836595T3 (en)	2017-12-29	Compositions and methods for inhibiting ALAS1 gene expression
DK2872153T3 (en)	2019-05-20	ACCELLULAR PRO-TOLEROGENIC COMPOSITIONS AND METHOD OF MANUFACTURE
DK3144001T3 (en)	2021-11-15	Compositions of selenoorganic compounds and methods of their use
DK3137596T3 (en)	2019-09-02	COMPOSITIONS AND PROCEDURES FOR MODULATION OF COMPLEMENT FACTOR B EXPRESSION
DK3164380T3 (en)	2022-03-28	INHIBITORS OF LIGHT-SPECIFIC DEMETHYLASE-1
DK3071215T3 (en)	2020-03-23	COMPOSITIONS AND METHODS FOR TREATMENT OF PULMONAL HYPERTENSION
DK3394272T5 (en)	2024-09-30	COMPOSITIONS AND METHODS FOR EFFECTIVE TARGETING OF TRANSGENES
DK3292873T3 (en)	2019-06-03	Combination of vaccination and inhibition of PD-1 pathway
DK3143026T3 (en)	2024-09-30	COMPOUNDS AND COMPOSITIONS FOR INDUCTION OF CHONDROGENESIS
IL255998A (en)	2018-01-31	Compositions and methods for inhibiting gene expression of hif2alpha
EP3632467C0 (en)	2023-09-27	INHIBITORS OF COMPLEMENT FACTOR H
DK3083683T3 (en)	2021-01-25	COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF FATTY COLLECTIONS
DK3204352T3 (en)	2020-09-28	Inhibitors of lysine-gingipain
DK2921050T3 (en)	2021-03-15	PROCEDURE FOR APPLICATION OF PLANT PROTECTION AGENTS
DK2968220T3 (en)	2021-06-14	PROCEDURES AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
DK3237619T3 (en)	2020-11-09	COMPOSITIONS AND PROCEDURES TO INHIBIT EXPRESSION OF ADAMTS-5 AND ADAM17

Movatterモバイル変換

DK3052628T3 - COMPOSITIONS AND PROCEDURES FOR INHIBITING EXPRESSION OF ALAS1 GENET - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=51932569

Family Applications (1)

Country Status (37)

Families Citing this family (11)

Family Cites Families (245)

Also Published As

Similar Documents